Siglec-8
Siglec-8 is an inhibitory Siglec whose expression is remarkably restricted to eosinophils, mast cells and, at low levels, basophils, making it the most specific cell-surface marker of eosinophils identified to date and a prime therapeutic target in eosinophilic disease. Siglec-8 is a type I transmembrane protein with a V-set binding domain recognizing a sialylated lactosamine-based glycan (6'-sulfo-sialyl Lewis X and related structures with preference for α2,3-linked sialic acid and 6-sulfation) and a cytoplasmic tail containing ITIM and ITIM-like motifs. Ligand engagement or antibody crosslinking induces two distinct death programs in Siglec-8-bearing cells: eosinophil apoptosis accelerated by IL-5 or GM-CSF priming, and mast cell apoptosis without degranulation. This dual pro-apoptotic property is exceptional among Siglecs and underlies lirentelimab (AK002), an anti-Siglec-8 antibody in clinical trials for eosinophilic gastritis, eosinophilic esophagitis, chronic spontaneous urticaria and indolent systemic mastocytosis.
-
Siglec-8 Recombinant Proteins (4)
- Species:
- Source:
- Species:
- Source:
- Species:
- Source:
- Species:
- Source:
Recombinant Protein Expression Service
- Codon Optimization
- Gene Synthesis
- Construction of Expression Vector
- Strain Screening
- Protein Expression
- Purification & QC
- Protein Delivery
- Formula: Human
- Molecular Weight: Sf9 insect cells
The EpCAM/TROP1 protein serves as an important homogeneous interacting molecule that promotes direct contact between intestinal epithelial cells (IEC) and intraepithelial lymphocytes (IEL) in the mucosal epithelium. This feature helps establish an immune barrier against mucosal infections. EpCAM/TROP1 Protein, Human (His-SUMO) is the recombinant human-derived EpCAM/TROP1 protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag.
